Voriconazole

Active ingredient: Voriconazole

In short: Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.

Forms & strengthsPowder for Oral Suspension Voriconazole for Oral Suspension is supplied as a white to off-white powder in 100 mL high density polyethylene (HDPE) bottles. …
LabelSlate Run Pharmaceuticals, LLC
Label updatedNov 16, 2026

What is Voriconazole used for?

Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were

Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of

Aspergillusother than

A. fumigatus .

Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of candidemia in non-neutropenic patients and the following

Candidainfections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds

.

Voriconazole for oral suspension is indicated in adults and pediatric patients (2 years of age and older) for the treatment of esophageal candidiasis (EC)

.

Voriconazole for oral suspension is indicated for the treatment of serious fungal infections caused by

Scedosporium apiospermum(asexual form of

Pseudallescheria boydii) and

Fusariumspp

.including

Fusarium solani, in adults and pediatric patients (2 years of age and older) intolerant of, or refractory to, other therapy

.

Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. …

Voriconazole dosage

Administer voriconazole oral suspension at least one hour before or after a meal.

See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous voriconazole on Day 1 followed by the recommended maintenance dose (RMD) regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of voriconazole may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg intravenously; a 300 mg oral dose achieves an exposure similar to 4 mg/kg intravenously

.

See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer.

See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.

Infection | Loading Dose | Maintenance Dose

Increase dose when voriconazole for oral suspension is co-administered with phenytoin or efavirenz

(7); Decrease dose in patients with hepatic impairment (

2.5).

In healthy volunteer studies, the 200 mg oral every 12 hours dose provided an exposure (AUCÏ„) similar to a 3 mg/kg intravenous infusion every 12 hours dose; the 300 mg oral every 12 hours dose provided an exposure (AUCÏ„) similar to a 4 mg/kg intravenous infusion every 12 hours dose (

12).

Intravenous Infusion | Intravenous Infusion | Oral Tablets

Adult patients who weigh less than 40 kg should receive half of the oral maintenance dose. | Oral Suspension

Invasive Aspergillosis

In a clinical study of IA, the median duration of intravenous voriconazole therapy was 10 days (range 2 to 85 days). The median duration of oral voriconazole therapy was 76 days (range 2 to 232 days) (

14.1). | 6 mg/kg every 12 hours for the first 24 hours | 4 mg/kg every 12 hours | 200 mg every 12 hours | 5 mL every 12 hours

Candidemia in Non-neutropenic Patients and Other Deep Tissue

CandidaInfections | 6 mg/kg every 12 hours for the first 24 hours | 3-4 mg/kg every 12 hours

In clinical trials, patients with candidemia received 3 mg/kg intravenous infusion every 12 hours as primary therapy, while patients with other deep tissue

Candida infections received 4 mg/kg every 12 hours as salvage therapy. Appropriate dose should be based on the severity and nature of the infection. | 200 mg every 12 hours | 5 mL every 12 hours

Esophageal Candidiasis | Not Evaluated

Not evaluated in patients with EC. …

How to take Voriconazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Visual Disturbances

Patients should be instructed that visual disturbances such as blurring and sensitivity to light may occur with the use of voriconazole.

Photosensitivity

Advise patients of the risk of photosensitivity (with or without concomitant methotrexate), accelerated photoaging, and skin cancer.

Advise patients that voriconazole can cause serious photosensitivity and to immediately contact their healthcare provider for new or worsening skin rash.

Advise patients to avoid exposure to direct sun light and to use measures such as protective clothing and sunscreen with high sun protection factor (SPF).

Embryo-Fetal Toxicity

Advise female patients of the potential risks to a fetus.

Advise females of reproductive potential to use effective contraception during treatment with voriconazole.

This product’s labeling may have been updated. For the most recent prescribing information, please visit www.slaterunpharma.com or call 1-888-341-9214.

Manufactured by: Zhejiang Poly Pharm. Co., Ltd., No. …

Warnings & precautions

Do not take this medicine if: Voriconazole for Oral Suspension is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Caution should be used when prescribing voriconazole to patients with hypersensitivity to other azoles.

Coadministration of pimozide, quinidine or ivabradine with voriconazole is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences

of torsade de pointes

.

Coadministration of voriconazole with sirolimus is contraindicated because voriconazole significantly increases sirolimus concentrations

.

Coadministration of voriconazole with rifampin, carbamazepine, long-acting barbiturates, or St John’s Wort is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations

significantly

.

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations

.

Coadministration of voriconazole with high-dose ritonavir (400 mg every 12 hours) is contraindicated because ritonavir (400 mg every 12 hours) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole

.

Coadministration of voriconazole with rifabutin is contraindicated since voriconazole significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations

. …

Voriconazole side effects

The following serious adverse reactions are described elsewhere in the labeling:

Hepatic Toxicity

Arrhythmias and QT Prolongation

Visual Disturbances

Severe Cutaneous Adverse Reactions

Photosensitivity

Renal Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Overview:The most frequently reported adverse reactions in the adult therapeutic trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%), hallucinations (2.4%). The adverse reactions which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash, and visual disturbances

.

The data described in Table 4 reflect exposure to voriconazole in 1655 patients in nine therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and nonneutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and nontherapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11-90, including 51 patients aged 12-18 years), and was 78% White and 10% Black. …

Drug interactions

Voriconazole is metabolized by cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Therefore, inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively. Voriconazole is a strong inhibitor of CYP3A4, and also inhibits CYP2C19 and CYP2C9. Therefore, voriconazole may increase the plasma concentrations of substances metabolized by these CYP450 isoenzymes.

Tables 10 and 11 provide the clinically significant interactions between voriconazole and other medical products.

Drug/Drug Class (Mechanism of Interaction by the Drug) | Voriconazole Plasma Exposure (C

maxand AUC

τafter 200 mg every 12 hours) | Recommendations for Voriconazole Dosage Adjustment/Comments

Rifampin

Results based on

in vivo clinical studies generally following repeat oral dosing with 200 mg every 12 hours voriconazole to healthy subjects

and Rifabutin

(CYP450 Induction) | Significantly Reduced | Contraindicated

Efavirenz (400 mg every 24 hours)

Results based on

in vivo clinical study following repeat oral dosing with 400 mg every 12 hours for 1 day, then 200 mg every 12 hours for at least 2 days voriconazole to healthy subjects

(CYP450 Induction) | Significantly Reduced | Contraindicated

Efavirenz (300 mg every 24 hours)

(CYP450 Induction) | Slight …

About this medicine

Voriconazole, an azole antifungal agent is available as a powder for oral suspension. The structural formula is:

Voriconazole is designated chemically as (2R,3S)-2-(2,4- difluorophenyl) -3- (5-fluoro- 4- pyrimidinyl)-1-(1

H-1,2,4-triazol-1-yl)-2butanol with an empirical formula of C

16H

14F

3N

5O and a molecular weight of 349.3.

Voriconazole, USP drug substance is a white to light-colored powder.

Voriconazole for Oral Suspension is a white to off-white powder providing a white to off-white, orange-flavored suspension when reconstituted. Bottles containing 45 grams powder for oral suspension, which contain 3 g of voriconazole, are intended for reconstitution with water to produce a suspension containing 40 mg/mL voriconazole, USP. The inactive ingredients include anhydrous citric acid, colloidal silicon dioxide, orange flavor, sodium benzoate, sodium citrate dihydrate, sucrose, titanium dioxide, and xanthan gum.

How it works: Voriconazole is an antifungal drug . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2b262849-9a29-44a2-9b9d-2378f771379c. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin